H.C. Wainwright lowered the firm’s price target on Fractyl Health (GUTS) to $8 from $9 and keeps a Buy rating on the shares after Fractyl announced midpoint randomized cohort results from the ongoing REMAIN-1 trial evaluating the Revita DMR procedure for weight loss after GLP-1 RA discontinuation. The change in the firm’s target is based primarily on adjustment of the fully diluted share count following the significant September fundraise and increasing the firm’s projected chance of success for Revita to 60% from 40% based on the positive REMAIN-1 midpoint cohort efficacy and safety results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GUTS:
- Fractyl Health Announces $60M Stock Offering Pricing
- Fractyl Health Reveals Promising REMAIN-1 Study Results
- Fractyl Health prices 60M shares at $1.00 in underwritten offering
- Fractyl Health announces REMAIN-1 study met 3-month efficacy endpoint
- Fractyl Health initiated with a Buy at H.C. Wainwright